Condition: Pancreatic Adenocarcinoma · Sponsor: Baylor Research Institute
Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with chemotherapy in metastasis (with FOLFIRINOX) and localized disease (with gemcitabine/abraxane/cisplatin), a phase 2 study with anakinra in combination with perioperative chemotherapy for patients with PDAC is being proposed.
This description comes directly from the study's public registry record.
Page Blas, MA · (214) 818-7879 · page.blas@bswhealth.org
Joyce Ghormley · (214) 818-8961 · Joyce.Ghormley@BSWHealth.org
Always discuss trial participation with your own doctor first.
| Baylor University Medical Center, Charles A Sammons Cancer Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04926467